TTP-αL Inhibitors
TTP-αL Inhibitors primarily include chemicals that inhibit enzymes in the PI3K signaling pathway, such as PI3K itself, mTOR, and AKT. These inhibitors exert their effects through various mechanisms. Some, such as LY294002, Wortmannin, BKM120, PI-103, BEZ235, ZSTK474, and GDC-0941, directly inhibit PI3K, the key enzyme in the pathway that TTP-αL is involved in. The inhibition of PI3K disrupts the signaling cascade, leading to decreased functional activity of TTP-αL as a downstream effector of this signaling pathway.
Other inhibitors, including Rapamycin, AZD8055, Everolimus, and KU-0063794, target mTOR, a downstream component of the PI3K pathway. By inhibiting mTOR, these chemicals disrupt the PI3K signaling pathway, indirectly leading to decreased functional activity of TTP-αL. A-443654 is an ATP-competitive inhibitor of AKT kinases, another integral part of the PI3K pathway. By inhibiting AKT, A-443654 can disrupt the PI3K signaling pathway, leading to decreased functional activity of TTP-αL.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphatidylinositol 3-kinases (PI3K). TTP-αL is a downstream effector of PI3K signaling. The inhibition of PI3K by LY294002 disrupts the signaling cascade, thus leading to the functional inactivity of TTP-αL. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Its inhibition of PI3K disrupts the signaling pathway that TTP-αL is involved in, decreasing TTP-αL's functional activity. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120 inhibits PI3K, a key component of the signaling pathway that TTP-αL is involved in. Its inhibition of PI3K can lead to decreased functional activity of TTP-αL. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a downstream effector of the PI3K pathway. The inhibition of mTOR disrupts the PI3K signaling pathway, indirectly leading to decreased functional activity of TTP-αL. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive mammalian target of rapamycin kinase inhibitor. Its inhibition of mTOR disrupts the PI3K signaling pathway, indirectly leading to decreased functional activity of TTP-αL. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor. Its inhibition of mTOR disrupts the PI3K signaling pathway, indirectly leading to decreased functional activity of TTP-αL. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is an ATP-competitive inhibitor of PI3K family members. Its inhibition of PI3K can lead to decreased functional activity of TTP-αL. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
BEZ235 inhibits both PI3K and mTOR. Its inhibition of these key enzymes disrupts the PI3K signaling pathway, leading to decreased functional activity of TTP-αL. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 selectively inhibits class I phosphatidylinositol 3-kinase. Its inhibition of PI3K can lead to decreased functional activity of TTP-αL. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent, selective inhibitor of class I PI3 kinase. Its inhibition of PI3K can lead to a decrease in the functional activity of TTP-αL. | ||||||